Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Emergency Use Authorizations During the COVID-19 Pandemic

Emergency Use Authorizations During the COVID-19 Pandemic This Viewpoint uses the FDA’s Emergency Use Authorization (EUA) of hydroxychloroquine for COVID-19 treatment to emphasize the costs of premature regulatory authorizations to public health and trust, and proposes the use of advisory committees, requirements for postmarketing surveillance, and adherence to standards of transparency for any future EUAs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Emergency Use Authorizations During the COVID-19 Pandemic

JAMA , Volume 324 (13) – Oct 6, 2020

Loading next page...
 
/lp/american-medical-association/emergency-use-authorizations-during-the-covid-19-pandemic-i0v5BxdaLK

References (10)

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2020.16253
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint uses the FDA’s Emergency Use Authorization (EUA) of hydroxychloroquine for COVID-19 treatment to emphasize the costs of premature regulatory authorizations to public health and trust, and proposes the use of advisory committees, requirements for postmarketing surveillance, and adherence to standards of transparency for any future EUAs.

Journal

JAMAAmerican Medical Association

Published: Oct 6, 2020

There are no references for this article.